### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Ty	pe Responses	s)															
Name and Address of Reporting Person * Holley Danica				2. Issuer Name and Ticker or Trading Symbol							5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) 2 BETHESDA METRO CENTER, SUITE 440				Global Medical REIT Inc. [GMRE]  3. Date of Earliest Transaction (Month/Day/Year) 03/03/2020							Director 10% Owner X Officer (give title below) Other (specify below) Chief Operating Officer						
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
BETHES	SDA, MD 2	20814										_ Form filed by	y More than One	e Reporting Perso	on		
(City	y)	(State)	(Zip)			Tab	le I -	Non-De	rivati	ve Securiti	es Acquire	d, Dispose	d of, or Ben	eficially Ow	ned		
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Year			2A. Deemed Execution Date, is any (Month/Day/Year		te, if Co	(Instr. 8)		(A) or Disposed		d of (D) Owned Follo				Ownership Form: I Direct (D)		Nature ndirect neficial nership str. 4)	
							Code	V	Amo	ount (A) or	Price				(I) (Instr. 4)		
Reminder:	h class of securities	s beneficial	eneficially owned directly or indirectly.  Persons who respond to the collection of information contained in this form are not required to respond unles:							ation	SEC	C 1474	4 (9-02)				
													ontrol num		ie		
										d of, or Bei ertible secu		wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if	4. Transaction Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable		7. Title an of Underly Securities (Instr. 3 an	ring		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Owner Form of Deriva Securit Direct or Indi	ship of tive y: (D)	(Instr. 4)	
				Code	V	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr.	4)	
LTIP Unit (Right to Buy)	<u>(2)</u>	03/03/2020		A		12,344	ļ	(2	Ĺ	(2)	Common Stock	12,344	\$ 0	65,473	D		
LTIP Unit (Right to Buy)	(2)	03/03/2020		A		3,905		<u>(2</u>	)	(2)	Common Stock	3,905	\$ 0	69,378	D		
LTIP Unit (Right to Buy)	(2)	03/03/2020		A		20,780	)	<u>(2</u>	)	(2)	Common Stock	20,780	\$ 0	90,158	D		

## **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Holley Danica 2 BETHESDA METRO CENTER, SUITE 440 BETHESDA, MD 20814			Chief Operating Officer				

#### **Signatures**

/s/ Danica Holley	03/05/2020
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors determined on March 3, 2020 that 50% of the LTIP Units vested and became nonforfeitable as a result of meeting certain market based performance criteria as of December 31, 2019
- (1) and 50% of the LTIP Units will vest on March 3, 2021, pursuant to the grant award agreement stipulations. The performance-based LTIP Units were awarded pursuant to an LTIP Unit annual award vesting agreement, the form of which was filed as Exhibit 99.2 to the Issuer's Current Report on Form 8-K filed on March 7, 2019, and pursuant to the Issuer's 2016 Equity Incentive Plan.
- (2) As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date.
- LTIP Units vest in equal one-third installments on March 3 of 2021, 2022 and 2023. The LTIP Units were awarded pursuant to an LTIP Unit vesting agreement, the form of which was (3) filed as Exhibit 99.2 to the Issuer's Current Report on Form 8-K filed on March 5, 2020, and pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan.
- The Issuer's Board of Directors determined on March 3, 2020 that 50% of the LTIP Units vested and became nonforfeitable as a result of meeting certain market based performance criteria as of February 28, 2020 and 50% of the LTIP Units will vest on March 3, 2021, pursuant to the grant award agreement stipulations. The performance-based LTIP Units were awarded pursuant to an LTIP Unit performance-based vesting agreement, the form of which was filed as Exhibit 99.4 to the Issuer's Current Report on Form 8-K filed on March 6, 2017, and pursuant to the Issuer's 2016 Equity Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.